A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma

Trial Details

NCT ID
NCT06566586
Phase
PHASE2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • TQB3702 tablets+Chemotherapy regimen
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Lanzhou, Gansu, China|36.05701,103.83987
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guigang, Guangxi, China|23.11603,109.59472
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • The subjects voluntarily joined the study, signed the informed consent, and the compliance was good;
  • Age: 18 years old ≤ age (when signing the informed consent) ≤75 years old; Eastern cooperative oncology group (ECOG) score: 0-2; Expected survival …
  • Histologically confirmed B-cell lymphomas of the following types that meet the 2022 World Health Organization (WHO) diagnostic criteria:
  • Relapsed/refractory indolent B-cell lymphoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →